Kriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged Mice

Kriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged Mice

– A single intramuscular administration extended health span and lifespan and produced sustained benefits across multiple organ systems in naturally aged mice –

– Findings reinforce the systemic biology underlying Kriya's native FGF21 gene therapy candidate in development for Steatotic Liver Disease –

Kriya Therapeutics, Inc. (“Kriya”), a biotechnology company committed to building durable medicines that can scale, today announced the publication of preclinical data demonstrating that a single intramuscular administration of an AAV vector expressing native FGF21 extended both health and lifespan in naturally aged mice. The study, titled AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations, was led by Professor Fátima Bosch in the Center for Animal Biotechnology and Gene Therapy, at the Universitat Autònoma de Barcelona (UAB) and appears in Molecular Therapy, the founding journal of the American Society of Gene & Cell Therapy (ASGCT).

"These data show the remarkable breadth of FGF21 biology, with a single administration driving durable benefits across organs well beyond the liver,” said Shankar Ramaswamy, MD, Co-Founder and CEO of Kriya Therapeutics. “These whole-body benefits in aged animals reinforce our conviction in native FGF21 gene therapy, and we remain focused on advancing KRIYA-497, our one-time gene therapy candidate expressing human native FGF21, for people living with steatotic liver disease and other conditions FGF21 is well positioned to address.”